Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial
Clinical Trials Arena
Related Posts
Post navigation
Previous Post
Gain hopes to prove Parkinson’s drug’s potential next year after phase 1 win for allosteric modulator
Next Post
In the clinic for Aug. 30, 2024
Latest Articles
Clear Filters
September 8, 2022
Gain Therapeutics to Present Data at Upcoming Medical Meetings
Read More
May 23, 2023
FORCE Family Office Webinar
Read More
March 1, 2022
Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences
Read More
Close
